Profound Medical Corp. (PROF) stock
PROFNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$7.85+0.17 (+2.21%)
Close on Nov 11, 2026Market cap $286.78MP/E –Yield –
Profound Medical EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was $1.41, up 25.9% from the year before. The highest annual figure on record is $1.50 in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.41 | +25.9% |
| FY2024 | Dec 31, 2024 | $1.12 | -16.4% |
| FY2023 | Dec 31, 2023 | $1.34 | -2.9% |
| FY2022 | Dec 31, 2022 | $1.38 | -8.0% |
| FY2021 | Dec 31, 2021 | $1.50 | +20.0% |
| FY2020 | Dec 31, 2020 | $1.25 | -8.8% |
| FY2019 | Dec 31, 2019 | $1.37 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.21 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.26 | -172.2% |
| Q1 FY2026 | Mar 31, 2026 | $0.19 | -50.0% |
| Q3 FY2025 | Sep 30, 2025 | -$0.26 | -192.9% |
| Q2 FY2025 | Jun 30, 2025 | -$0.52 | -292.6% |
| Q1 FY2025 | Mar 31, 2025 | $0.36 | – |
| Q3 FY2024 | Sep 30, 2024 | $0.38 | – |
| Q2 FY2024 | Jun 30, 2024 | $0.28 | – |
| Q1 FY2024 | Mar 31, 2024 | $0.27 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?